Publication:
The New Formulations of Immunoglobulin Replacement Therapies and Future Aspects

Simple item page
dc.contributor.authorAYDINER, ELİF
dc.contributor.authorsKarakoç-Aydıner E.
dc.date.accessioned2024-08-12T08:50:00Z
dc.date.available2024-08-12T08:50:00Z
dc.date.issued2024-01-01
dc.description.abstractImmunoglobulin replacement therapy (IgRT) stands as the established method of treatment for numerous inborn errors of immunity (IEI). Over the past six decades, there have been notable advancements in the dosing, processing, and administration routes of IgRT for IEI. Intravenous immunoglobulin has proven to be an effective treatment method, typically administered every 3 to 4 weeks. Traditional subcutaneous intravenous immunoglobulin (SCIG) is equally effective in maintaining biological IgG levels, with smaller doses administered daily every 2 weeks. F-SCIG is also equally effective and is typically administered every 3 to 4 weeks, in which patients are first required to administer hyaluronidase and then the gammaglobulin. Compared to less concentrated SCIG products, those with higher concentrations allow for the infusion of a smaller volume, less time spent on infusion, increased interval between infusions, and improved health-related quality of life. In addition, high-concentration products are reported to be similarly effective and well-tolerated by patients compared to lower-concentration SCIG and IVIG bioequivalents. High-concentration SCIG products, such as Cutaquig/Gammanorm (16.5% IgG) and Hizentra, Cuvitru, and Xembify (20% IgG), are available in the market. Overall results demonstrated that high-concentration SCIG products were efficient and well-tolerated, and allowed successful self-administration in individuals with IEI. A precise and personalized approach to IgRT is essential for improving outcomes in patients with IEI. The quest for new IgRT formulations and improved ancillary tools for SCIG aims to lower the occurrence of infections and complications related to them by enhancing adherence to long-term IgRT.
dc.identifier.citationKarakoç-Aydıner E., "The New Formulations of Immunoglobulin Replacement Therapies and Future Aspects", Turkish Journal of Immunology, cilt.12, ss.83-87, 2024
dc.identifier.doi10.4274/tji.galenos.2023.43265
dc.identifier.endpage87
dc.identifier.issn1301-109X
dc.identifier.startpage83
dc.identifier.urihttps://avesis.marmara.edu.tr/api/publication/1a7b709d-ad11-4aef-8a08-0ffdf7d5d04c/file
dc.identifier.urihttps://hdl.handle.net/11424/297535
dc.identifier.volume12
dc.language.isoeng
dc.relation.ispartofTurkish Journal of Immunology
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTıp
dc.subjectYaşam Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTemel Bilimler
dc.subjectMedicine
dc.subjectLife Sciences
dc.subjectHealth Sciences
dc.subjectNatural Sciences
dc.subjectKlinik Tıp (MED)
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectKlinik Tıp
dc.subjectİmmünoloji
dc.subjectALERJİ
dc.subjectClinical Medicine (MED)
dc.subjectLife Sciences (LIFE)
dc.subjectCLINICAL MEDICINE
dc.subjectIMMUNOLOGY
dc.subjectALLERGY
dc.subjectİmmünoloji ve Alerji
dc.subjectImmunology and Allergy
dc.subjectImmunology
dc.subjectFacilitated subcutaneous immunoglobulin
dc.subjecthigh concentration immunoglobulin
dc.subjectimmunoglobulin replacement therapy
dc.subjectinborn errors of immunity
dc.subjectintravenous immunoglobulin
dc.subjectsubcutaneous immunoglobulin
dc.titleThe New Formulations of Immunoglobulin Replacement Therapies and Future Aspects
dc.typearticle
dspace.entity.typePublication
local.avesis.id1a7b709d-ad11-4aef-8a08-0ffdf7d5d04c
local.indexed.atSCOPUS
relation.isAuthorOfPublication80233b91-5a8c-45e1-bf76-c54825ea0175
relation.isAuthorOfPublication.latestForDiscovery80233b91-5a8c-45e1-bf76-c54825ea0175

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
file.pdf
Size:
450.14 KB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs